Stock Scorer

Lineage Cell Therapeutics, Inc. (LCTX)

Lineage Cell Therapeutics, Inc. reported revenue of 1.1M USD for the quarter ending 30 June 2026, down 61.3% from 2.8M a year earlier.

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than filled in. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD. The same series drawn ›

As last reported

The newest period the filing supports for each figure, in USD.
FigurePeriodAmountYear on year
Revenue Q2 '26 · ending 30 June 2026 1.1M -61.3%
Gross Profit Q4 '23 · ending 31 December 2023 1.8M +1.0%
Operating Income Q2 '26 · ending 30 June 2026 -8.9M —
Net Income Q2 '26 · ending 30 June 2026 1.5M —
Cost of Revenue Q1 '25 · ending 31 March 2025 36K -63.3%
Operating Cash Flow Q2 '26 · ending 30 June 2026 -7.2M —
Free Cash Flow Q2 '26 · ending 30 June 2026 -7.4M —
Shares Outstanding Q2 '26 · ending 30 June 2026 261.5M +15.7%
EPS Q1 '26 · ending 31 March 2026 -0.29 —

Revenue and profit by financial year

As filed, in USD. A year the filing does not support is not listed.
YearEnding RevenueOperating IncomeNet IncomeFree Cash Flow
20252025-12-31 14.6M-36.6M-63.5M-19.4M
20242024-12-31 9.5M-21.5M-18.6M-23.7M
20232023-12-31 8.9M-24.7M-21.5M-29.2M
20222022-12-31 14.7M-22.5M-26.3M646K
20212021-12-31 4.3M-49.2M-43M-23.9M
20202020-12-31 1.8M-26.4M-20.6M-19.8M
20192019-12-31 3.5M-38.9M-11.7M-32.4M
20182018-12-31 5M-41.8M-46M-31.4M
20172017-12-31 3.5M-38.9M-20M-31.8M
20162016-12-31 5.9M-59M33.6M-44.6M

Every period

Revenue Quarterly

PeriodEndingRevenue
Q2 '262026-06-301.1M
Q1 '262026-03-311.7M
Q4 '252025-12-316.6M
Q3 '252025-09-303.7M
Q2 '252025-06-302.8M
Q1 '252025-03-311.5M
Q4 '242024-12-312.9M
Q3 '242024-09-303.8M
Q2 '242024-06-301.4M
Q1 '242024-03-311.4M
Q4 '232023-12-312.1M
Q3 '232023-09-301.2M
Q2 '232023-06-303.2M
Q1 '232023-03-312.4M
Q4 '222022-12-311.9M
Q3 '222022-09-303M
Q2 '222022-06-304.6M
Q1 '222022-03-315.2M
Q4 '212021-12-311.2M
Q3 '212021-09-302.3M

Gross Profit Quarterly

PeriodEndingGross Profit
Q4 '232023-12-311.8M
Q3 '232023-09-301.1M
Q2 '232023-06-303.1M
Q1 '232023-03-312.3M
Q4 '222022-12-311.8M
Q3 '222022-09-302.8M
Q2 '222022-06-304.3M
Q1 '222022-03-315.1M
Q4 '212021-12-31964K
Q3 '212021-09-301.3M
Q2 '212021-06-30387K
Q1 '212021-03-31279K
Q4 '202020-12-31241K
Q3 '202020-09-30469K
Q2 '202020-06-30311K
Q1 '202020-03-31420K
Q4 '192019-12-311.1M
Q3 '192019-09-30453K
Q2 '192019-06-30672K
Q1 '192019-03-31860K

Operating Income Quarterly

PeriodEndingOperating Income
Q2 '262026-06-30-8.9M
Q1 '262026-03-31-7.6M
Q4 '252025-12-31-6.5M
Q3 '252025-09-30-3.8M
Q2 '252025-06-30-19.8M
Q1 '252025-03-31-6.5M
Q4 '242024-12-31-5.1M
Q3 '242024-09-30-3.8M
Q2 '242024-06-30-5.9M
Q1 '242024-03-31-6.7M
Q4 '232023-12-31-6.4M
Q3 '232023-09-30-6.7M
Q2 '232023-06-30-5M
Q1 '232023-03-31-6.6M
Q4 '222022-12-31-6.6M
Q3 '222022-09-30-5.3M
Q2 '222022-06-30-4.2M
Q1 '222022-03-31-6.4M
Q4 '212021-12-31-28.2M
Q3 '212021-09-30-6.8M

Net Income Quarterly

PeriodEndingNet Income
Q2 '262026-06-301.5M
Q1 '262026-03-31-4.8M
Q4 '252025-12-31851K
Q3 '252025-09-30-29.8M
Q2 '252025-06-30-30.5M
Q1 '252025-03-31-4.1M
Q4 '242024-12-31-3.3M
Q3 '242024-09-30-3M
Q2 '242024-06-30-5.8M
Q1 '242024-03-31-6.5M
Q4 '232023-12-31-4.8M
Q3 '232023-09-30-7.1M
Q2 '232023-06-30-5.2M
Q1 '232023-03-31-4.4M
Q4 '222022-12-31-6.4M
Q3 '222022-09-30-6.1M
Q2 '222022-06-30-6.8M
Q1 '222022-03-31-7.1M
Q4 '212021-12-31-29M
Q3 '212021-09-30-7.8M

Cost of Revenue Quarterly

PeriodEndingCost of Revenue
Q1 '252025-03-3136K
Q4 '242024-12-31154K
Q3 '242024-09-3038K
Q2 '242024-06-3044K
Q1 '242024-03-3198K
Q4 '232023-12-31256K
Q3 '232023-09-30169K
Q2 '232023-06-30127K
Q1 '232023-03-31119K
Q4 '222022-12-31102K
Q3 '222022-09-30235K
Q2 '222022-06-30215K
Q1 '222022-03-31176K
Q4 '212021-12-31204K
Q3 '212021-09-30985K
Q2 '212021-06-30125K
Q1 '212021-03-31112K
Q4 '202020-12-31114K
Q3 '202020-09-30102K
Q2 '202020-06-3075K

Operating Cash Flow Quarterly

PeriodEndingOperating Cash Flow
Q2 '262026-06-30-7.2M
Q1 '262026-03-31-8.1M
Q4 '252025-12-31-4.9M
Q3 '252025-09-30-3.6M
Q2 '252025-06-30-5.5M
Q1 '252025-03-31-4.9M
Q4 '242024-12-31-6.3M
Q3 '242024-09-30-5.8M
Q2 '242024-06-30-5.2M
Q1 '242024-03-31-5.8M
Q4 '232023-12-31-6M
Q3 '232023-09-30-5M
Q2 '232023-06-30-6.3M
Q1 '232023-03-31-11.2M
Q4 '222022-12-31-8.3M
Q3 '222022-09-30-5.5M
Q2 '222022-06-30-7.1M
Q1 '222022-03-3121.9M
Q4 '212021-12-31-5.9M
Q3 '212021-09-30-4.8M

Free Cash Flow Quarterly

Operating cash flow minus capital expenditure.

PeriodEndingFree Cash Flow
Q2 '262026-06-30-7.4M
Q1 '262026-03-31-8.1M
Q4 '252025-12-31-5.3M
Q3 '252025-09-30-3.6M
Q2 '252025-06-30-5.6M
Q1 '252025-03-31-5M
Q4 '242024-12-31-6.7M
Q3 '242024-09-30-5.9M
Q2 '242024-06-30-5.2M
Q1 '242024-03-31-5.8M
Q4 '232023-12-31-6.1M
Q3 '232023-09-30-5.2M
Q2 '232023-06-30-6.5M
Q1 '232023-03-31-11.4M
Q4 '222022-12-31-8.3M
Q3 '222022-09-30-5.8M
Q2 '222022-06-30-7.2M
Q1 '222022-03-3121.9M
Q4 '212021-12-31-6M
Q3 '212021-09-30-4.9M

Shares Outstanding Quarterly

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

PeriodEndingShares Outstanding
Q2 '262026-06-30261.5M
Q1 '262026-03-31261.2M
Q3 '252025-09-30228.9M
Q2 '252025-06-30228.4M
Q1 '252025-03-31226.1M
Q3 '242024-09-30188.8M
Q2 '242024-06-30188.8M
Q1 '242024-03-31182.9M
Q3 '232023-09-30174.9M
Q2 '232023-06-30170.6M
Q1 '232023-03-31170.1M
Q3 '222022-09-30169.8M
Q2 '222022-06-30169.7M
Q1 '222022-03-31169.6M
Q3 '212021-09-30167.6M
Q2 '212021-06-30162.9M
Q1 '212021-03-31158.7K
Q3 '202020-09-30150M
Q2 '202020-06-30149.8K
Q1 '202020-03-31149.8M

EPS TTM

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.

PeriodEndingEPS
Q1 '262026-03-31-0.29
Q4 '252025-12-31-0.28
Q3 '252025-09-30-0.29
Q2 '252025-06-30-0.18
Q1 '252025-03-31-0.08
Q4 '242024-12-31-0.10
Q3 '242024-09-30-0.12
Q2 '242024-06-30-0.14
Q1 '242024-03-31-0.14
Q4 '232023-12-31-0.13
Q3 '232023-09-30-0.13
Q2 '232023-06-30-0.13
Q1 '232023-03-31-0.14
Q4 '222022-12-31-0.15
Q3 '222022-09-30-0.29
Q2 '222022-06-30-0.30
Q1 '222022-03-31-0.29
Q1 '202020-03-31-0.40
Q4 '192019-12-31-0.04
Q3 '192019-09-30-0.37